Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes.
暂无分享,去创建一个
O. Olopade | T. Rebbeck | W. Foulkes | B. Weber | P. Tonin | J. Garber | A. Godwin | J. Brunet | G. Lenoir | S. Narod | R. Moslehi | A. Liede | J. Abrahamson | P. A. Futreal | H. Lynch | M. Daly | H. Lynch | C. Lerman | P. Ghadirian | C. Lerman | J. Garber | J. Wagner-Costalas | J. Brunet | Barbara L. Weber | Josephine Wagner-Costalas | Patricia N. Tonin | Gilbert M. Lenoir | Henry T. Lynch | P. Futreal | S. A. Narod | Judy Garber | H. T. Lynch
[1] C. Labrie,et al. Almost Exclusive Androgenic Action of Dehydroepiandrosterone in the Rat Mammary Gland. , 1998, Endocrinology.
[2] J. Holtzman,et al. Correspondence re: G. C. Kabat et al., Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol., Biomark. Prev., 6: 505-509, 1997. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[3] J. Goméz,et al. Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Effect of 12-Month Dehydroepiandrosterone Replacement Therapy on Bone, Vagina, and Endometrium in Postmenopausal Women , 2022 .
[4] J. Simard,et al. Characterization of the effects of the novel non‐steroidal antiestrogen EM‐800 on basal and estrogen‐induced proliferation of T‐47D, ZR‐75‐1 and MCF‐7 human breast cancer cells in vitro , 1997, International journal of cancer.
[5] C. Labrie,et al. Effect of Dehydroepiandrosterone on Bone Mass, Serum Lipids, and Dimethylbenz(a)anthracene-Induced Mammary Carcinoma in the Rat. , 1997, Endocrinology.
[6] J. Simard,et al. (S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen. , 1997, Journal of medicinal chemistry.
[7] J. Sparano,et al. Urinary estrogen metabolites and breast cancer: a case-control study. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[8] P. Hartge,et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.
[9] F. Speizer,et al. Birthweight as a risk factor for breast cancer , 1997 .
[10] D. Kiel,et al. Bone mass and the risk of breast cancer among postmenopausal women. , 1997, The New England journal of medicine.
[11] D. Zaridze,et al. Genetic polymorphisms and breast cancer risk. , 1997, Journal of the American Medical Association (JAMA).
[12] J. Robins,et al. Birthweight as risk factor for breast cancer , 1997, The Lancet.
[13] B. Stall. Brithweight as risk factor for breast cancer , 1997, The Lancet.
[14] J. Robins,et al. Birthweight as risk factor for breast cancer (multiple letters) [1] , 1997 .
[15] J. Robins,et al. BIRTHWEIGHT AS RISK FACTOR FOR BREAST CANCER. AUTHORS' REPLY , 1997 .
[16] S. Seal,et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene , 1997, Nature Genetics.
[17] J. Freudenheim,et al. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. , 1996, JAMA.
[18] B Fisher,et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. , 1996, Journal of the National Cancer Institute.
[19] C. Labrie,et al. High bioavailability of dehydroepiandrosterone administered percutaneously in the rat. , 1996, The Journal of endocrinology.
[20] B. Trock,et al. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. , 1996, JAMA.
[21] J. Simard,et al. The 3β-Hydroxysteroid Dehydrogenase/Isomerase Gene Family: Lessons from Type II 3β-HSD Congenital Deficiency , 1996 .
[22] L. Cannon-Albright,et al. Risk modifiers in carriers of brca1 mutations , 1995, International journal of cancer.
[23] J. Simard,et al. DHEA and Peripheral Androgen and Estrogen Formation: Intracrinology , 1995, Annals of the New York Academy of Sciences.
[24] P. Tonin,et al. A large multisite cancer family is linked to BRCA2. , 1995, Journal of medical genetics.
[25] V. Jordan,et al. Hormonal treatment of advanced breast cancer. , 1995, Surgical oncology clinics of North America.
[26] S. Hilsenbeck,et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. , 1995, Journal of the National Cancer Institute.
[27] D. Easton,et al. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.
[28] B. Bengtsson,et al. Serum insulin‐like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin , 1994, Clinical endocrinology.
[29] M. Thun,et al. Cigarette smoking and risk of fatal breast cancer. , 1994, American journal of epidemiology.
[30] N. Skakkebaek,et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. , 1994, The Journal of clinical endocrinology and metabolism.
[31] J. Bringer,et al. Androgen receptor gene mutation in male breast cancer. , 1993, Human molecular genetics.
[32] E. Thomas,et al. The impact of cigarette smoking on the plasma concentrations of gonadotrophins, ovarian steroids and androgens and upon the metabolism of oestrogens in the human female. , 1993, Human reproduction.
[33] A. Ashworth,et al. Control of aromatase in breast cancer cells and its importance for tumor growth , 1993, The Journal of Steroid Biochemistry and Molecular Biology.
[34] J. Bonneterre,et al. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. , 1993, European journal of cancer.
[35] M. Stratton,et al. A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome , 1992, Nature Genetics.
[36] A. Wakeling,et al. ICI 182,780, a new antioestrogen with clinical potential , 1992, The Journal of Steroid Biochemistry and Molecular Biology.
[37] R. Frairia,et al. Smoking effects on the hormonal balance of fertile women. , 1992, Hormone research.
[38] C. Osborne,et al. Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. , 1991, Journal of the National Cancer Institute.
[39] K. Schulz,et al. Androgen sensitivity of the new human breast cancer cell line MFM-223. , 1991, Cancer research.
[40] F. Labrie,et al. Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice. , 1991, Cancer research.
[41] D. Schaid,et al. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis , 1991, Cancer.
[42] C. la Vecchia,et al. The antiestrogenic effect of cigarette smoking in women. , 1990, American journal of obstetrics and gynecology.
[43] J. Simard,et al. Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer. , 1990, Endocrinology.
[44] B. Rimer,et al. The Older Smoker: Status, Challenges and Opportunities for Intervention , 1990 .
[45] V. Jordan,et al. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. , 1989, Cancer research.
[46] F. Labrie,et al. Additive inhibitory effects of bromocryptine (CB-154) and medroxyprogesterone acetate (MPA) on dimethylbenz[a]anthracene (DMBA)-induced mammary tumors in the rat. , 1989, European journal of cancer & clinical oncology.
[47] J. Simard,et al. Inhibitory effect of estrogens on GCDFP-15 mRNA levels and secretion in ZR-75-1 human breast cancer cells. , 1989, Molecular endocrinology.
[48] J. Baron,et al. Cigarette smoking and breast cancer. , 1989, American journal of epidemiology.
[49] N. Davidson,et al. The role of estrogens in growth regulation of breast cancer. , 1989, Critical reviews in oncogenesis.
[50] M. Dumont,et al. Antagonism between estrogens and androgens on GCDFP-15 gene expression in ZR-75-1 cells and correlation between GCDFP-15 and estrogen as well as progesterone receptor expression in human breast cancer. , 1989, Journal of steroid biochemistry.
[51] C. Labrie,et al. Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. , 1988, Endocrinology.
[52] S. Robinson,et al. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. , 1988, Cancer research.
[53] C. Osborne,et al. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. , 1987, European journal of cancer & clinical oncology.
[54] C. la Vecchia,et al. Cigarette smoking and the risk of endometrial cancer. , 1987, European journal of cancer & clinical oncology.
[55] H. Bradlow,et al. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. , 1986, The New England journal of medicine.
[56] F. Labrie,et al. Stimulation of cell proliferation and estrogenic response by adrenal C19-delta 5-steroids in the ZR-75-1 human breast cancer cell line. , 1986, Cancer research.
[57] C. Christiansen,et al. Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause. , 1985, The New England journal of medicine.
[58] W. Miller,et al. Androgen receptor activity in human breast cancer and its relationship with oestrogen and progestogen receptor activity. , 1985, European journal of cancer & clinical oncology.
[59] R. Bryan,et al. Androgen receptors in breast cancer , 1984, Cancer.
[60] V. Jordan,et al. Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: Problems and potential for future clinical applications , 1983, Breast cancer research and treatment.
[61] B. Edwards,et al. Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. , 1983, Annals of internal medicine.
[62] N. Weiss,et al. Effect of Weight, Smoking, and Estrogen Use on the Risk of Hip and Forearm Fractures in Postmenopausal Women , 1982, Obstetrics and gynecology.
[63] B. Macmahon,et al. Cigarette smoking and urinary estrogens. , 1982, The New England journal of medicine.
[64] A. Bélanger,et al. Characteristics of binding to estrogen, androgen, progestin, and glucocorticoid receptors in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and their hormonal control. , 1980, Cancer research.
[65] G. Hortobagyi,et al. Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. , 1979, Cancer research.
[66] A. Schwartz. Inhibition of spontaneous breast cancer formation in female C3H(Avy/a) mice by long-term treatment with dehydroepiandrosterone. , 1979, Cancer research.
[67] F. Labrie,et al. Effects of estradiol and prolactin on steroid receptor levels in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and uterus in the rat. , 1978, Journal of steroid biochemistry.
[68] P. Kelly,et al. Inhibitory Effect of LHRH and Its Agonists on Testicular Gonadotrophin Receptors and Spermatogenesis in the Rat , 1978 .
[69] M. Caron,et al. Control of hormone receptor levels and growth of 7,12-dimethylbenz(a)anthracene-induced mammary tumors by estrogens, progesterone and prolactin. , 1977, Endocrinology.
[70] A. Segaloff. The use of androgens in the treatment of neoplastic disease , 1977 .
[71] G. Trams,et al. Specific binding of estradiol and dihydrotestosterone in human mammary cancers. , 1977, Cancer research.
[72] J. Meites,et al. Counteraction by prolactin of androgen-induced inhibition of mammary tumor growth in rats. , 1974, Journal of the National Cancer Institute.
[73] A. Segaloff,et al. Hormonal therapy in cancer of the breast. I. The effect of testosterone propionate therapy on clinical course and hormonal excretion , 1951, Cancer.